Neuro-Oncology Practice Clinical Debate: Early treatment or observation for patients with newly diagnosed oligodendroglioma and small-volume residual disease. Issue 1 (27th June 2020)

• Record Type: Journal Article
• Authors: Fogh, Shannon E; Boreta, Lauren; Nakamura, Jean L; Johnson, Derek R; Chi, Andrew S; Kurz, Sylvia C
• Is Part Of: Neuro-oncology practice. Volume 8:Issue 1(2021)
• Page Start: 11
• Page End: 17
• Publication Date: 2020-06-27
• Subjects: cognition -- observation -- oligodendroglioma -- radiation -- toxicity; Brain -- Tumors -- Periodicals; Brain -- Cancer -- Periodicals; Nervous system -- Cancer -- Periodicals; 616.99481005
• DOI: 10.1093/nop/npaa037
• Languages: English
• ISSNs: 2054-2577

Abstract

Abstract: Advances in treatment of oligodendroglioma represent arguably the most significant recent development in the treatment of brain tumors, with multiple clinical trials demonstrating that median survival is approximately doubled in patients with World Health Organization grade II and III 1p/19q codeleted gliomas (ie, oligodendrogliomas) treated with procarbazine, lomustine, vincristine chemotherapy and radiation vs radiation alone. However, chemoradiotherapy itself is not without morbidity, including both short-term toxicities primarily related to chemotherapy and longer-term cognitive issues likely due to radiation. Patients and physicians both desire maximally effective therapy with minimal toxicity, and it remains unclear whether some patients with macroscopic residual disease after surgery can safely delay therapy, to avoid or delay toxicity, while simultaneously preserving the full benefits of treatment. In this article, experts in the field discuss the rationale for the approaches of up-front treatment with chemoradiotherapy and initial observation, respectively.